You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

217 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Nov 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer
Guidelines and Advice
Status: Current
ID: GL1-10
Version: 4
Mar 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Rectal
Intent: Neoadjuvant
Jan 2026
Drug
Other Name(s): Poteligeo®
Regimen
Cancer Type:
Central Nervous System
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Updated
Mar 2026

Pages